{"id":"anti-hyperglycemic-agents","safety":{"commonSideEffects":[{"rate":null,"effect":"Hypoglycemia"},{"rate":null,"effect":"Gastrointestinal disturbance"},{"rate":null,"effect":"Weight gain"},{"rate":null,"effect":"Lactic acidosis (metformin-associated)"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"This is a broad drug class rather than a single agent, encompassing multiple mechanistic approaches to lower blood glucose in diabetes. Common mechanisms include stimulating pancreatic beta cells to release insulin (sulfonylureas, meglitinides), improving cellular insulin sensitivity (thiazolidinediones, metformin), inhibiting glucose reabsorption in the kidney (SGLT2 inhibitors), or slowing carbohydrate digestion (alpha-glucosidase inhibitors).","oneSentence":"Anti-hyperglycemic agents work by reducing blood glucose levels through various mechanisms including insulin secretion enhancement, insulin sensitivity improvement, or glucose absorption inhibition.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:42:12.230Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Type 2 diabetes mellitus"},{"name":"Hyperglycemia management"}]},"trialDetails":[{"nctId":"NCT03492580","phase":"","title":"A Study for Comparison of Canagliflozin Versus Alternative Antihyperglycemic Treatments on Risk of Heart Failure Hospitalization and Amputation for Participants With Type 2 Diabetes Mellitus and the Subpopulation With Established Cardiovascular Disease","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2018-02-22","conditions":"Diabetes Mellitus, Type 2, Cardiovascular Diseases","enrollment":714582},{"nctId":"NCT02542631","phase":"NA","title":"Glycemic Control and Treatment Satisfaction Using Finesse Versus Pen for Initiating Bolus Insulin Dosing in Type 2 Diabetes Patients","status":"COMPLETED","sponsor":"Calibra Medical, Inc.","startDate":"2015-08-01","conditions":"Diabetes Mellitus, Type 2","enrollment":278},{"nctId":"NCT03862963","phase":"NA","title":"Lifestyle Intervention to Treat Diabetes in the Marshall Islands","status":"COMPLETED","sponsor":"University of Alabama at Birmingham","startDate":"2006-06-01","conditions":"Type 2 Diabetes Mellitus","enrollment":138},{"nctId":"NCT05822674","phase":"","title":"Variable Effects of Anti-diabetics on Stress Hyperglycemia Ratio","status":"COMPLETED","sponsor":"University of Diyala","startDate":"2022-01-01","conditions":"Type 2 Diabetes","enrollment":80},{"nctId":"NCT01986881","phase":"PHASE3","title":"Cardiovascular Outcomes Following Ertugliflozin Treatment in Type 2 Diabetes Mellitus Participants With Vascular Disease, The VERTIS CV Study (MK-8835-004)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2013-11-04","conditions":"Type 2 Diabetes Mellitus","enrollment":8246},{"nctId":"NCT05417880","phase":"PHASE3","title":"Vitamin D, K2 Plus Empagliflozin Combination in Type Two Diabetes Mellitus","status":"UNKNOWN","sponsor":"Scotmann Pharmaceuticals","startDate":"2022-08","conditions":"Diabetes Mellitus","enrollment":340},{"nctId":"NCT04146155","phase":"PHASE4","title":"Efficacy and Safety of Liraglutide in Type 2 Diabetes With Lower Extremity Arterial Disease","status":"UNKNOWN","sponsor":"Second Affiliated Hospital, School of Medicine, Zhejiang University","startDate":"2020-05-01","conditions":"Type 2 Diabetes, Peripheral Vascular Disorder Due to Diabetes Mellitus","enrollment":200},{"nctId":"NCT02925312","phase":"NA","title":"MedStar Health Type 2 Diabetes Pathway to Control","status":"COMPLETED","sponsor":"Medstar Health Research Institute","startDate":"2014-11","conditions":"Type 2 Diabetes Mellitus, Hyperglycemia","enrollment":419},{"nctId":"NCT03249506","phase":"","title":"Cardiovascular Outcomes in Participants With Type 2 Diabetes Mellitus (T2DM)","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2016-05-12","conditions":"Diabetes Mellitus, Type 2","enrollment":25358},{"nctId":"NCT03169959","phase":"PHASE1","title":"A Study to Evaluate the Food Effect on Drug Availability, Pharmacokinetic (PK) Properties, Safety and Tolerability of Two Different Dose Combination Therapy of Saxagliptin/Dapagliflozin/Metformin Extended-release (XR) Against Individual Component Co-administration.","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2017-05-29","conditions":"Type 2 Diabetes Mellitus","enrollment":85},{"nctId":"NCT03233178","phase":"","title":"Measurement of Alanine Aminotransaminase (ALT) Following Initiation of Antidiabetic Agents in Patients With Type 2 Diabetes in a Real-world Clinical Setting: a Retrospective Cohort Study","status":"COMPLETED","sponsor":"LMC Diabetes & Endocrinology Ltd.","startDate":"2017-01","conditions":"T2DM (Type 2 Diabetes Mellitus), Fatty Liver, NAFLD","enrollment":4000},{"nctId":"NCT01939496","phase":"PHASE4","title":"Evaluation of Blood Pressure Reduction, Safety, and Tolerability of Canagliflozin in Patients With Hypertension and Type 2 Diabetes Mellitus on Stable Doses of Anti-hyperglycemic and Anti-hypertensive Agents","status":"COMPLETED","sponsor":"Janssen Scientific Affairs, LLC","startDate":"2013-10","conditions":"Diabetes Mellitus, Type 2, Hypertension","enrollment":171},{"nctId":"NCT00000620","phase":"PHASE3","title":"Action to Control Cardiovascular Risk in Diabetes (ACCORD)","status":"COMPLETED","sponsor":"National Heart, Lung, and Blood Institute (NHLBI)","startDate":"1999-09","conditions":"Atherosclerosis, Cardiovascular Diseases, Hypercholesterolemia","enrollment":10251},{"nctId":"NCT02802644","phase":"PHASE4","title":"The Effect of DPP4 Inhibitor on Vasclular Healing","status":"UNKNOWN","sponsor":"Chung-Ang University","startDate":"2016-06","conditions":"Acute Coronary Syndrome, Diabetes Mellitus, Type 2","enrollment":66},{"nctId":"NCT00388050","phase":"NA","title":"Diabetes Medication Choice","status":"COMPLETED","sponsor":"Mayo Clinic","startDate":"2006-07","conditions":"Type 2 Diabetes","enrollment":85},{"nctId":"NCT01060059","phase":"","title":"Exenatide and Basal Insulins Use in the Real Setting: an Observational Study in Patients With Type 2 Diabetes","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2010-04","conditions":"Type 2 Diabetes Mellitus","enrollment":888},{"nctId":"NCT00147836","phase":"NA","title":"Evaluation of the Effects of Different Interventions on Glycemic Control in Newly-Diagnosed Type 2 Diabetic Patients","status":"COMPLETED","sponsor":"Sun Yat-sen University","startDate":"2004-09","conditions":"Type 2 Diabetes Mellitus","enrollment":436}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["glimepiride (Amaryl)","metformin (Glucophage)","repaglinide (Gluconorm, Prandin)","rosiglitazone (Avandia)","pioglitazone (Actos)"],"phase":"phase_3","status":"active","brandName":"Anti-hyperglycemic Agents","genericName":"Anti-hyperglycemic Agents","companyName":"National Heart, Lung, and Blood Institute (NHLBI)","companyId":"national-heart-lung-and-blood-institute-nhlbi","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Anti-hyperglycemic agents are used to treat conditions such as type 2 diabetes mellitus, cardiovascular diseases, and hypertension. Examples of these agents include oral hypoglycemic agents like empagliflozin, which have been studied in combination with other substances such as vitamin D and K2 in clinical trials.","enrichmentLevel":3,"visitCount":2,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}